Evaluation of the effectiveness and safety of anti-obesity drugs - an update on the current state of knowledge on available and investigational drugs
Authors:
- Katarzyna CichońKCKatarzyna Cichoń
- Małgorzata ChyćkoMCMałgorzata Chyćko
- Julia CzarnotaJCJulia Czarnota
- Agata KromerAKAgata Kromer
- Magdalena Alicja ZapałaMZMagdalena Alicja Zapała
- Agnieszka ŚrodońAŚAgnieszka Środoń
- Joanna WilkJWJoanna Wilk
- Małgorzata Maria CholewaMCMałgorzata Maria Cholewa
- Agnieszka GawryśAGAgnieszka Gawryś
- Monika ŁapajMŁMonika Łapaj
Open Access
- 29 May 2023
- journal article
- research article
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 35 (1) , 94-112
Abstract
Introduction and purpose of the work: Disturbing epidemiological data indicate that obesity has become a global problem and has reached the size of a worldwide epidemic. The search for effective methods of combating obesity seems to be an important step in preventing cardiovascular diseases and numerous metabolic complications. The aim of the study is to assess the effectiveness and safety of available drugs used in the treatment of obesity in accordance with the current state of knowledge and to present new pharmacological options. State of knowledge: Pharmacotherapy provides overweight and obese adults with the opportunity to support weight reduction in the event of failure of lifestyle modifications. Currently registered drugs for the treatment of obesity are orlistat, lorcaserin, liraglutide and combination preparations: phentermine/topiramate and naltrexone SR/bupropion SR. Summary: Among the currently available drugs for obesity, the most effective are phentermine/topiramate and liraglutide. Research is also underway on the use of new substances that promote weight loss. The latest data on semaglutide and tirzepatide have better efficacy results compared to currently available drugs with a similar safety profile. The latest data on semaglutide and tirzepatide improve the efficacy results of current drugs while maintaining a similar safety profile. It seems that the best way to lose excessive body weight should be an individualized approach to the treatment of obesity among patients, taking into account i.a. degree of obesity, comorbidities, contraindications, patient preferences, cost and availability of treatment. In clinical practice, when choosing a drug, we should pay attention to side effects and find a balance between effectiveness and safety. In addition to weight loss, the use of anti-obesity drugs has many additional benefits, including improvement of the cardiometabolic profile, reduction of glucose, insulin and lipids in the blood.Keywords
This publication has 28 references indexed in Scilit:
- Retracted: Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trialsThe Lancet, 2022
- Safety and Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Children and Adolescents with Obesity: A Meta-AnalysisThe Journal of Pediatrics, 2021
- Comparative efficacy and safety of 8 GLP-1RAs in patients with type 2 diabetes: A network meta-analysisDiabetes Research and Clinical Practice, 2021
- Efficacy and Safety of Phentermine/Topiramate in Adults with Overweight or Obesity: A Systematic Review and Meta‐AnalysisObesity, 2021
- Coadministration of lorcaserin and phentermine for weight management: A 12‐week, randomized, pilot safety studyObesity, 2017
- Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse EventsJAMA, 2016
- Gastrointestinal traits: individualizing therapy for obesity with drugs and devicesGastrointestinal Endoscopy, 2016
- Naltrexone/bupropion for obesity: An investigational combination pharmacotherapy for weight lossPharmacological Research, 2014
- Long-term Drug Treatment for ObesityJAMA, 2014
- Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adultsInternational Journal of Obesity, 2013